Skip to main content
Bharat Parenterals Limited logo

Bharat Parenterals Limited — Investor Relations & Filings

Ticker · 541096 ISIN · INE365Y01019 LEI · 335800P94TEP45XMI742 BSE.NS Manufacturing
Open in API
Filings indexed 10 across all filing types
Latest filing 2026-05-21 Report Publication Anno…
Country IN India
Listing BSE.NS 541096

About Bharat Parenterals Limited

https://www.bplindia.in/

Bharat Parenterals Limited specializes in the development, manufacture, and marketing of a diverse range of medicinal formulations. The organization operates advanced manufacturing facilities compliant with WHO-GMP standards, producing various dosage forms including small and large volume parenterals, tablets, capsules, liquid orals, dry syrups, and topical preparations. Its product portfolio addresses multiple therapeutic segments such as anti-infectives, cardiovascular, gastrointestinal, and analgesics. With a focus on research and development, the company maintains an extensive international presence, supplying products to markets across South East Asia, Africa, and Latin America. The company emphasizes quality assurance and regulatory compliance to deliver affordable healthcare solutions globally.

Recent filings

Filing Released Lang Actions
Newspaper publication of Audited Financial Results of the Quarter and Year ended on March 31, 2026.
Report Publication Announcement Classification · 95% confidence The document is a filing submitted to the stock exchange under SEBI’s Listing Obligations (Regulation 47), enclosing copies of a newspaper advertisement for the audited financial results (quarter and year ended March 31, 2026). It does not itself contain financial statements or detailed results but merely announces the publication of those results in the press and on the company’s website. This matches the “Report Publication Announcement” category, which covers notices that a report has been published or is available.
2026-05-21 English
Transcript of Earning Conference Call of Q4FY26.
Call Transcript Classification · 95% confidence The document is a full transcript of the company’s Q4 and FY ’26 earnings conference call (with moderator, opening remarks, financial results, and outlook), and it was submitted under Regulation 30. This matches the definition of a Call Transcript (CT).
2026-05-20 English
Audio Recording of Q4FY26 Earnings Conference Call
Regulatory Filings
2026-05-19 English
Investor Presentation for the Quarter and Year ended on March 31, 2026.
Investor Presentation Classification · 95% confidence The document is titled "INVESTOR PRESENTATION" and is provided pursuant to SEBI LODR Regulation 30, containing slide-style financial metrics, management commentary, segment disclosures, and strategic outlook for Q4 FY26 & Annual FY26. It is not merely an announcement but includes the full presentation content intended for investors. This matches the definition of an Investor Presentation (Code: IP).
2026-05-18 English
Appointment of Cost Auditor and Internal Auditor of the company.
Regulatory Filings Classification · 90% confidence The document is a formal SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 disclosure to BSE Limited regarding the re-appointment of the company’s Cost Auditor and Internal Auditor. It does not contain any financial statements, earnings data, board member changes, M&A, or dividend details. It is a compliance announcement under SEBI LODR rather than a full report or specific category filing. There is no dedicated category for auditor appointments, so the appropriate classification is Regulatory Filings (RNS), the fallback for miscellaneous regulatory disclosures.
2026-05-18 English
Board of Directors at its meeting held today, May 18, 2026, recommended a Final Dividend of Rs. 1/- Per Equity Share
Audit Report / Information Classification · 85% confidence The document is a formal SEBI LODR disclosure containing an Independent Auditor’s Report on the Standalone Annual Financial Results pursuant to Regulation 33, along with the audited financial results table. It is not a full annual report (10-K) with MD&A, nor a simple press‐style earnings release (ER), nor an interim/quarterly report (IR). Instead, it primarily comprises the standalone audit report and the audited financial statements, fitting the definition of Audit Report / Information.
2026-05-18 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.